AQW 18905/17-22 Written question to the Minister of Health
To ask the Minister of Health to detail his plans for enabling patients in Northern Ireland to access the Duchenne muscular dystrophy drug Translarna on the NHS, in line with England.
Asked by Claire Sugden MLA on 14 May 2021
- Answered
- Written
- After due date
- Tabled
- 14 May 2021
- Answer due by
- 1 June 2021
- Answered
- 17 August 202195 days after tabling
- Department
- Department of Health
- Priority question
- No
Answer
Highly specialised technologies recommended by the National Institute for Health and Care Excellence (NICE) are available to all suitable patients in Northern Ireland within the parameters set by NICE.
Ataluren (Translarna) for treating Duchenne muscular dystrophy (HST3) was recommended for use by NICE in July 2016.